Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Antonio, Texas Clinical Trials

A listing of Antonio, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (34) clinical trials

Assessment of an Orthopedic Surgery Rotation on Musculoskeletal Competency in Emergency Medicine Residency Training

Patient commonly present with orthopedic injuries in the emergency department. Musculoskeletal education has not historically been emphasized in American medical schools, and the effectiveness of an orthopedic surgery rotation has not been well studied in emergency medicine (EM) training. Competency in musculoskeletal education has been tested previously with a validated ...

Phase N/A

1.01 miles

Learn More »

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline ...

Phase N/A

1.01 miles

Learn More »

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). Approximately 500 adult subjects with SLE will be randomized in a 1:1:1:1:1 ratio ...

Phase

1.47 miles

Learn More »

Efficacy & Safety of TD-1473 in Ulcerative Colitis

This protocol consists of 3 separate studies: an 8-week Phase 2b dose-finding induction study, an 8-week dose-confirming Phase 3 induction study, and a 44-week Phase 3 maintenance study. Subjects who respond to induction will enter the maintenance study; those who do not will receive TD-1473 during extended induction. The safety ...

Phase

1.47 miles

Learn More »

Stress Hydrocortisone In Pediatric Septic Shock

Sepsis represents the most common cause of childhood mortality worldwide. In the United States alone, 200 cases of pediatric sepsis are diagnosed each day, with an associated hospital mortality rate of 5-10% and health care expenditures now approaching $5 billion annually. Moreover, nearly one third of children admitted to pediatric ...

Phase

1.95 miles

Learn More »

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Phase

4.62 miles

Learn More »

ICON Early Phase Services is conducting a research study for healthy adults ages 18-55. This study is being done to test the study drug’s effect on the heart rate. Vital signs, ECGs, physical examinations and pregnancy, drug and alcohol screens will be performed. Blood and urine samples will also be ...

Phase

4.62 miles

Learn More »

ICON  Early  Phase  Services  is  conducting  a  research  study  for  healthy  adults  ages 18-65. This study is being  done  to test a  potential treatment for neurodegenerative diseases  (e.g.,  Parkinson's  and Alzheimer's). Vital  signs,  ECGs,  physical  examinations  and  pregnancy,  drug  and  alcohol  screens will be performed.  Blood  and  urine  samples  will ...

Phase

4.62 miles

Learn More »

Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Solid Tumors

ORIC-101 is a small molecule GR antagonist being developed for the treatment of patients with solid tumor malignancies. Mechanistically, ORIC-101 inhibits GR transcriptional activity and blocks the pro-survival signals mediated by the activated nuclear receptor. This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antitumor ...

Phase

7.18 miles

Learn More »

HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Eligible participants will receive single doses of HEPLISAV-B at Weeks 0, 4, 8, and 16 and will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the immunogenicity and safety over a 68-week period.

Phase

7.18 miles

Learn More »